Yahoo
NasdaqCM - Delayed Quote USD

Tiziana Life Sciences Ltd (TLSA)

0.6102 -0.0589 (-8.80%)
At close: 4:00:00 PM EST
Chart Range Bar
Loading chart for TLSA
  • Previous Close 0.6691
  • Open 0.6800
  • Bid 0.6615 x 200
  • Ask 0.6960 x 200
  • Day's Range 0.6100 - 0.6847
  • 52 Week Range 0.5700 - 1.9000
  • Volume 394,994
  • Avg. Volume 739,453
  • Market Cap (intraday) 77.654M
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2100
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 7.96
  • Moby Rating Neutral

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.

www.tizianalifesciences.com

10

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/10/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TLSA
59.05%
S&P 500 (^GSPC)
9.87%

1-Year Return

TLSA
65.13%
S&P 500 (^GSPC)
10.08%

3-Year Return

TLSA
3.42%
S&P 500 (^GSPC)
70.34%

5-Year Return

TLSA
57.03%
S&P 500 (^GSPC)
61.85%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY21
Revenue --
Earnings --
Profit Margin 0.00%

Q2

FY19

Q1

FY20

Q2

FY20

Q4

FY21

0
0.0%

Analyst Insights

View More

Analyst Price Targets

6.96
7.96 Average
0.6102 Current
8.95 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/22/2026
Analyst BTIG
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 7 -> 7

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -103.16%

  • Return on Equity (ttm)

    -780.60%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -25.19M

  • Diluted EPS (ttm)

    -0.2100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.18M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -6.38M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: